A new blood test for predicting multiple sclerosis risk
Researchers have developed a novel diagnostic autoantibody assay targeting a consensus motif, designed to predict the risk of developing Epstein-Barr virus-related multiple sclerosis. This advancement in neuroimmunology and neuroinflammation research represents a significant step towards a biomarker-driven approach for this complex neurodegenerative and demyelinating disease. The assay, detailed in Neurology Neuroimmunology & Neuroinflammation, could enable earlier identification of at-risk individuals, allowing for closer monitoring and potentially earlier intervention strategies in clinical neurology.
Study Significance: This development directly addresses a critical need in multiple sclerosis research for reliable, early risk prediction tools. For neurologists and clinical researchers, it opens a pathway to stratify patients based on EBV-related autoimmunity, potentially refining clinical trial enrollment and personalizing preventive strategies. The move towards assay-based diagnostics could shift the paradigm from reactive treatment to proactive risk management in neuroinflammatory disorders.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
